vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.4%, a 8.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 0.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-7.4M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -3.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
ANIP vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $330.4M |
| Net Profit | $27.5M | $7.9M |
| Gross Margin | — | 27.3% |
| Operating Margin | 14.1% | 3.6% |
| Net Margin | 11.1% | 2.4% |
| Revenue YoY | 29.6% | 0.1% |
| Net Profit YoY | 367.5% | -2.7% |
| EPS (diluted) | $1.14 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | $247.1M | $332.0M | ||
| Q3 25 | $227.8M | $332.6M | ||
| Q2 25 | $211.4M | $334.3M | ||
| Q1 25 | $197.1M | $330.0M | ||
| Q4 24 | $190.6M | $343.8M | ||
| Q3 24 | $148.3M | $353.3M | ||
| Q2 24 | $138.0M | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | $27.5M | $5.2M | ||
| Q3 25 | $26.6M | $11.1M | ||
| Q2 25 | $8.5M | $10.4M | ||
| Q1 25 | $15.7M | $8.1M | ||
| Q4 24 | $-10.3M | $11.1M | ||
| Q3 24 | $-24.2M | $14.2M | ||
| Q2 24 | $-2.3M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | — | 27.1% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | — | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 14.1% | 2.6% | ||
| Q3 25 | 15.9% | 4.5% | ||
| Q2 25 | 6.6% | 4.5% | ||
| Q1 25 | 13.3% | 3.5% | ||
| Q4 24 | -2.3% | 4.5% | ||
| Q3 24 | -13.8% | 5.3% | ||
| Q2 24 | 3.7% | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 11.1% | 1.6% | ||
| Q3 25 | 11.7% | 3.3% | ||
| Q2 25 | 4.0% | 3.1% | ||
| Q1 25 | 8.0% | 2.5% | ||
| Q4 24 | -5.4% | 3.2% | ||
| Q3 24 | -16.3% | 4.0% | ||
| Q2 24 | -1.7% | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $1.14 | $0.29 | ||
| Q3 25 | $1.13 | $0.63 | ||
| Q2 25 | $0.36 | $0.59 | ||
| Q1 25 | $0.69 | $0.45 | ||
| Q4 24 | $-0.45 | $0.60 | ||
| Q3 24 | $-1.27 | $0.75 | ||
| Q2 24 | $-0.14 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $117.4M |
| Total Assets | $1.4B | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $285.6M | $2.1M | ||
| Q3 25 | $262.6M | $1.3M | ||
| Q2 25 | $217.8M | $2.5M | ||
| Q1 25 | $149.8M | $444.0K | ||
| Q4 24 | $144.9M | $349.0K | ||
| Q3 24 | $145.0M | $127.0K | ||
| Q2 24 | $240.1M | $110.0K |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $540.7M | $124.6M | ||
| Q3 25 | $505.8M | $132.1M | ||
| Q2 25 | $436.8M | $134.4M | ||
| Q1 25 | $418.6M | $138.0M | ||
| Q4 24 | $403.7M | $154.6M | ||
| Q3 24 | $405.9M | $167.4M | ||
| Q2 24 | $455.8M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | $1.4B | $365.6M | ||
| Q3 25 | $1.4B | $374.2M | ||
| Q2 25 | $1.3B | $373.6M | ||
| Q1 25 | $1.3B | $368.2M | ||
| Q4 24 | $1.3B | $357.8M | ||
| Q3 24 | $1.3B | $369.9M | ||
| Q2 24 | $920.8M | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | $-7.4M |
| FCF MarginFCF / Revenue | 11.8% | -2.2% |
| Capex IntensityCapex / Revenue | 0.5% | 1.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $19.7M | ||
| Q3 25 | $44.1M | $23.3M | ||
| Q2 25 | $75.8M | $18.4M | ||
| Q1 25 | $35.0M | $249.0K | ||
| Q4 24 | $15.9M | $21.8M | ||
| Q3 24 | $12.5M | $31.0M | ||
| Q2 24 | $17.4M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $29.1M | $16.7M | ||
| Q3 25 | $38.0M | $19.8M | ||
| Q2 25 | $71.8M | $14.2M | ||
| Q1 25 | $32.5M | $-3.9M | ||
| Q4 24 | $13.5M | $20.9M | ||
| Q3 24 | $7.7M | $27.5M | ||
| Q2 24 | $13.0M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | 11.8% | 5.0% | ||
| Q3 25 | 16.7% | 6.0% | ||
| Q2 25 | 34.0% | 4.3% | ||
| Q1 25 | 16.5% | -1.2% | ||
| Q4 24 | 7.1% | 6.1% | ||
| Q3 24 | 5.2% | 7.8% | ||
| Q2 24 | 9.4% | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 1.3% | 1.3% | ||
| Q4 24 | 1.3% | 0.3% | ||
| Q3 24 | 3.2% | 1.0% | ||
| Q2 24 | 3.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 3.82× | ||
| Q3 25 | 1.66× | 2.11× | ||
| Q2 25 | 8.87× | 1.76× | ||
| Q1 25 | 2.23× | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
KFRC
Segment breakdown not available.
